Breaking News, Financial News

Financial Report: Pfizer 3Q10

Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptos

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 3Q10 3Q Revenues: $16.2 billion (+39%*) 3Q Earnings: $866 million (-70%*) YTD Revenues: $50.2 billion (+50%*) YTD Earnings: $5.4 billion (-32%*) Comments: Revenues in the quarter were boosted by $5.2 billion, or 44%, due to legacy Wyeth products, and negatively impacted by $458 million, or 4%, due to legacy Pfizer products, including the loss of exclusivity of Lipitor in Canada and Spain, as well as Camptosar in Europe. U.S. revenues were $7.1 billion (+48%) and Internation...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters